0941 GMT - News that Roche's tiragolumab drug candidate didn't meet the primary goal of a late-stage clinical trial in lung cancer doesn't come as a surprise for investors, Bryan Garnier says in a note. The Swiss pharmaceutical company released long-awaited data at final analysis for tiragolumab that showed the overall survival goal wasn't met. This was largely anticipated by the market in light of previous data, Bryan Garnier says. Roche had previously pointed at a limited efficacy in terms of progression-free survival and a miss relative to Merck's Keytruda in a separate arm of the same clinical program, the broker says. Shares fall 1%.(adria.calatayud@wsj.com)
(END) Dow Jones Newswires
November 26, 2024 04:41 ET (09:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.